These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1616 related articles for article (PubMed ID: 28314735)

  • 1. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.
    Adams LA; Anstee QM; Tilg H; Targher G
    Gut; 2017 Jun; 66(6):1138-1153. PubMed ID: 28314735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Scorletti E; Byrne CD
    Dig Dis; 2016; 34 Suppl 1():11-8. PubMed ID: 27548822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrahepatic Complications of Nonalcoholic Fatty Liver Disease.
    Chacko KR; Reinus J
    Clin Liver Dis; 2016 May; 20(2):387-401. PubMed ID: 27063276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease - A multisystem disease?
    Mikolasevic I; Milic S; Turk Wensveen T; Grgic I; Jakopcic I; Stimac D; Wensveen F; Orlic L
    World J Gastroenterol; 2016 Nov; 22(43):9488-9505. PubMed ID: 27920470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander.
    Vanni E; Marengo A; Mezzabotta L; Bugianesi E
    Semin Liver Dis; 2015 Aug; 35(3):236-49. PubMed ID: 26378641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
    Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
    Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.
    Li AA; Ahmed A; Kim D
    Gut Liver; 2020 Mar; 14(2):168-178. PubMed ID: 31195434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease.
    Targher G; Byrne CD
    Nat Rev Nephrol; 2017 May; 13(5):297-310. PubMed ID: 28218263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease and clinical outcomes in chronic kidney disease.
    Chinnadurai R; Ritchie J; Green D; Kalra PA
    Nephrol Dial Transplant; 2019 Mar; 34(3):449-457. PubMed ID: 29390103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis.
    Morrison AE; Zaccardi F; Khunti K; Davies MJ
    Liver Int; 2019 Mar; 39(3):557-567. PubMed ID: 30358050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease, metabolic goal achievement with incident cardiovascular disease and eGFR-based chronic kidney disease in patients with prediabetes and diabetes.
    Li M; Zhao Z; Qin G; Chen L; Lu J; Huo Y; Chen L; Zeng T; Xu M; Chen Y; Wang T; Wang S; Xu Y; Shi L; Tang X; Su Q; Yu X; Yan L; Wan Q; Chen G; Gao Z; Wang G; Shen F; Luo Z; Zhang Y; Liu C; Wang Y; Hu R; Ye Z; Wu S; Deng H; Yang T; Li Q; Qin Y; Mu Y; Zhao J; Ning G; Bi Y; Xu Y; Wang W
    Metabolism; 2021 Nov; 124():154874. PubMed ID: 34517014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?
    Targher G; Chonchol M; Pichiri I; Zoppini G
    J Endocrinol Invest; 2011; 34(7):544-51. PubMed ID: 21427524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cardiovascular Risk in Patients with Non-alcoholic Fatty Liver Disease].
    Kim HS; Cho YK
    Korean J Gastroenterol; 2017 Jun; 69(6):333-340. PubMed ID: 28637101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extrahepatic complications of non-alcoholic fatty liver disease: Its impact beyond the liver.
    Velarde-Ruiz Velasco JA; García-Jiménez ES; García-Zermeño KR; Morel-Cerda EC; Aldana-Ledesma JM; Castro-Narro GE; Cerpa-Cruz S; Tapia-Calderón DK; Mercado-Jauregui LA; Contreras-Omaña R
    Rev Gastroenterol Mex (Engl Ed); 2019; 84(4):472-481. PubMed ID: 31488310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes.
    Mantovani A; Turino T; Lando MG; Gjini K; Byrne CD; Zusi C; Ravaioli F; Colecchia A; Maffeis C; Salvagno G; Lippi G; Bonora E; Targher G
    Diabetes Metab; 2020 Sep; 46(4):296-303. PubMed ID: 31786361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals.
    Della Pepa G; Vetrani C; Lombardi G; Bozzetto L; Annuzzi G; Rivellese AA
    Nutrients; 2017 Sep; 9(10):. PubMed ID: 28954437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
    Muzurović E; Mikhailidis DP; Mantzoros C
    Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 81.